OncoMatch/Hodgkin Lymphoma (HL)/PD-L1 (CD274)

Hodgkin Lymphoma (HL)PD-L1 (CD274) Clinical Trials

Classical Hodgkin lymphoma (cHL) has among the highest PD-L1 expression of any cancer, driven by 9p24.1 amplification of PD-L1/PD-L2, making it exquisitely sensitive to PD-1 checkpoint inhibition. Pembrolizumab and nivolumab are FDA-approved for relapsed/refractory cHL; nivolumab plus AVD is now approved as frontline therapy for previously untreated stage III/IV cHL (age 12+), establishing IO as part of first-line treatment. Trials continue testing sequencing strategies, de-escalation in early-stage favorable disease, and post-transplant PD-1 maintenance.